Dr Reddy’s Secures USFDA Approval for First Generic Twice‑Yearly Injectable HIV Prevention Drug

In a landmark regulatory decision, the United States Food and Drug Administration granted Dr Reddy’s Laboratories permission to sell Lenacapavir, a long‑acting injectable designed to prevent HIV infection with biannual dosing. The drug, previously available only as a patented product, now enters the generic arena, offering a cost‑effective alternative for health systems and patients alike. Analysts predict that the entry of a generic version will compress prices, potentially expanding access in low‑ and middle‑income countries that have struggled with the high cost of existing prophylactics.

The approval follows years of clinical trials that demonstrated the drug’s safety and efficacy, as well as extensive negotiations with the FDA over manufacturing standards. Dr Reddy’s leveraged its robust production capabilities to meet stringent quality requirements, positioning itself as a key player in the global HIV prevention market. The move also underscores India’s growing influence in the pharmaceutical sector, where domestic firms increasingly challenge multinational incumbents.

The downstream impact includes a likely surge in procurement by public health programmes, a reduction in the financial burden on national HIV/AIDS budgets, and a possible shift in prevention strategies toward longer‑acting formulations. Moreover, the success may encourage other Indian manufacturers to pursue generic versions of advanced biologics, reshaping the competitive dynamics of the global drug .